Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment

References

• Neemann K, Freifeld A. Clostridium difficile–associated diarrhea in the oncology patient. J Oncol Pract. 2017;13(1):25–30.
   PubMed Web of Science ®Google Scholar
• Gupta A, Tariq R, Frank RD, et al. Trends in the incidence and outcomes of hospitalized cancer patients with Clostridium difficile infection: A nationwide analysis. J Natl Compr Canc Netw. 2017;15(4):466–472.
   PubMed Web of Science ®Google Scholar
• Khan A, Raza S, Batul SA, et al. The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Pat Antiinfect Drug Discov. 2012;7(2):157–170.
   PubMedGoogle Scholar
• Martínez-Meléndez A, Camacho-Ortiz A, Morfin-Otero R. Current knowledge on the laboratory diagnosis of Clostridium difficile infection. World J Gastroenterol. 2017;23(9):1552–1567.
   PubMed Web of Science ®Google Scholar
• Hall IC, Intestinal OE. Fora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficile. Am J Dis Child. 1935;49:390–402.
   Google Scholar
• Raza S, Baig MA, Russell H, et al. Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov. 2010;5(1):1–9.
   PubMedGoogle Scholar
• Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med. 1978;298:531–534.
   PubMed Web of Science ®Google Scholar
• Kamthan AG, Bruckner HW, Hirschman SZ, et al. Clostridium difficile diarrhea induced by cancer chemotherapy. Arch Intern Med. 1992;152(8):1715–1717.
   PubMedGoogle Scholar
• Lessa FC, Carolyn V, Clifford McDonald GL. Current Status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55(Suppl 2):S65–S70.
   PubMed Web of Science ®Google Scholar
• Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.
   PubMed Web of Science ®Google Scholar
• Tai E, Richardson LC, Townsend J, et al. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J. 2011;30(7):610–612.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–1548.
   PubMed Web of Science ®Google Scholar
• Souza MH, Melo-Filho AA, Rocha MF, et al. The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology. 1997;91(2):281–288.
   PubMed Web of Science ®Google Scholar
• Bauer KA, Johnston JEW, Wenzler E, et al. Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection. Anaerobe. 2017;48:1–6.
   PubMed Web of Science ®Google Scholar
• Cloud J, Noddin L, Pressman A. Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol. 2009;7(8):868–873.
   PubMed Web of Science ®Google Scholar
• Kamboj M, Xiao K, Kaltsas A, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027. Biol Blood Marrow Transplant. 2014;20:1626–1633.
   PubMed Web of Science ®Google Scholar
• Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand. J. Gastroenterol. 2009;44(1):74–78.
   PubMed Web of Science ®Google Scholar
• Scappaticci GB, Perissinotti AJ, Nagel JL, et al. Risk factors and impact of Clostridium difficile recurrence on haematology patients. J Antimicrob Chemother. 2017;72(5):1488–1495.
   PubMed Web of Science ®Google Scholar
• Chung MS, Kim J, Kang JO, et al. Impact of malignancy on Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. 2016;35(11):1771–1776.
   PubMed Web of Science ®Google Scholar
• Chopra T, Chandrasekar P, Salimnia H, et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant. 2011;25(1):E82–7.
   PubMed Web of Science ®Google Scholar
• Delgado A, Reveles I, Cabello F, et al. Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals. BMC Infectious Diseases. 2017;17:448.
   PubMed Web of Science ®Google Scholar
• Kamboj M, Son C, Cantu S, et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol. 2012;33(11):1162–1165.
   PubMed Web of Science ®Google Scholar
• Hebbard AI, Slavin MA, Reed C, et al. The epidemiology of Clostridium difficile infection in patients with cancer. Expert Rev Anti Infect Ther. 2016;14(11):1077–1085.
   PubMed Web of Science ®Google Scholar
• Brown KA, Khanafer N, Daneman N, et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326–2332.
   PubMed Web of Science ®Google Scholar
• Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol. 2005;3(5):442–448.
   PubMed Web of Science ®Google Scholar
• Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. Cmaj. 2004;171(1):33–38.
   PubMed Web of Science ®Google Scholar
• McCaleb RV, Gandhi AS, Clark SM, et al. Clinical outcomes of acid suppressive therapy use in hematology/oncology patients at an academic medical center. Ann Pharmacother. 2016;50(7):541–547.
   PubMed Web of Science ®Google Scholar
• Chul P, Ki-Eun H. Hak-Ryul H. Overview of Clostridium Difficile Infection in Cancer Patients. J Infect Dis Diagn. 2016;1:109.
   Google Scholar
• Hebbard AIT, Slavin MA, Reed C, et al. Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study. Support Care Cancer. 2017;25(6):1923–1930.
   PubMed Web of Science ®Google Scholar
• Mora AL, Salazar M, Pablo-Caeiro J, et al. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012;343(4):277–280.
   PubMed Web of Science ®Google Scholar
• Chang GY, Dembry LM, Banach DB. Epidemiology of Clostridium difficile infection in hospitalized oncology patients. Am J Infect Control. 2016;44(11):1408–1410.
   PubMed Web of Science ®Google Scholar
• Wang MS, Evans CT, Rodriguez T, et al. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2013;34(2):127–132.
   PubMed Web of Science ®Google Scholar
• Peretz A, Shlomo IB, Nitzan O, et al. Clostridium difficile infection: associations with chemotherapy, radiation therapy, and targeting therapy treatments. Curr Med Chem. 2016;23(39):4442–4449.
   PubMed Web of Science ®Google Scholar
• Fuereder T, Koni D, Gleiss A, et al. Risk factors for Clostridium difficile infection in hemato-oncological patients: a case control study in 144 patients. Sci Rep. 2016;6:31498.
   PubMed Web of Science ®Google Scholar
• Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17(1):109–113.
   PubMed Web of Science ®Google Scholar
• Morales Chamorro R, Serrano Blanch R, Méndez Vidal MJ, et al. Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. Clin Transl Oncol. 2005 7;Jul(6):258–261.
   Google Scholar
• Nielsen H, Daugaard G, Tvede M, et al. High prevalence of Clostridium difficile diarrhoea during intensive chemotherapy for disseminated germ cell cancer. Br J Cancer. 1992;66(4):666–667.
   PubMed Web of Science ®Google Scholar
• Emoto M, Kawarabayashi T, Hachisuga MD. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol. 1996;61(3):369–372.
   PubMed Web of Science ®Google Scholar
• Husain A, Aptaker L, Spriggs DR, et al. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol. 1998;71(1):104–107.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. . Clin Microbiol Infect.. 2014;20(Suppl 2):1–26.
   PubMed Web of Science ®Google Scholar
• Woodworth MH, Kraft CS. Diagnostic and therapeutic considerations for oncology patients with Clostridium difficile infection. Journal of Oncology Practice. 2017;13(1):31–32.
   PubMed Web of Science ®Google Scholar
• Erb S, Frei R, Stranden AM, et al. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients. Clin Microbiol Infect. 2015;21(11):998.e9-998.e15.
   PubMed Web of Science ®Google Scholar
• Ö Y, Altındiş M, Cufalı D, et al. A diagnostic algorithm for the detection of Clostridium difficile-associated diarrhea. Balkan Med J. 2016;33(1):80–86.
   PubMed Web of Science ®Google Scholar
• Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol. 2006;44(3):1145–1149.
   PubMed Web of Science ®Google Scholar
• Fenner L, Widmer AF, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol. 2008;46(1):328–330.
   PubMed Web of Science ®Google Scholar
• Larson AM, Fung AM, Fang FC. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol. 2010;48(1):124–130.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498.
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–307.
   PubMed Web of Science ®Google Scholar
• Belmares J, Gerding DN, Parada JP, et al. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007;55(6):495–501.
   PubMed Web of Science ®Google Scholar
• Yoon YK, Kim MJ, Sohn JW, et al. Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy. Support. Care Cancer. 2014;22(8):2039–2048.
   PubMed Web of Science ®Google Scholar
• Parmar S, Bhatt V, Yang J, et al. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. Journal of Oncology Pharmacy Practice. 2013;20(3):172–182.
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005 Jun 1;40(11):1586–1590.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections (Version I. 2018). https://www.nccn.org/professionals/physician_gls/PDF/infections.pdf. cited Apr 22, 2018
   Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431.
   PubMed Web of Science ®Google Scholar
• Esmaily-Fard A, Tverdek F, Crowther D, et al. The use of fidaxomicin for treatment of relapsed Clostridium difficileI nfections in patients with cancer. Pharmacotherapy: the Journal of Human Pharmacology and Drug Therapy. 2014;34(11):1220–1225.
   Google Scholar
• Comely OA, Miller MA, Fantin B, et al. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013;31(19):2493–2499.
   PubMed Web of Science ®Google Scholar
• Mathur H, Rea MC, Cotter PD. The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes. 2014;5(6):696–710.
   PubMed Web of Science ®Google Scholar
• Reveles KR, Backo JL, Corvino FA, et al. Fidaxomicin versus vancomycin as a first-line treatment for Clostridium difficile-associated diarrhea (CDAD) in specific patient populations: a pharmacoeconomic evaluation. Pharmacotherapy. 2017;37(12):1489–1497.
   PubMed Web of Science ®Google Scholar
• Rubio-Terrés C, Cobo Reinoso J, Grau Cerrato S, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. European Journal of Clinical Microbiology & Infectious Diseases. 2015;34(11):2213–2223.
   PubMed Web of Science ®Google Scholar
• Redman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25(10):1919–1929.
   PubMed Web of Science ®Google Scholar
• Martin J, Mawer D, Wilcox MH. Clostridium difficile: biological therapies. Curr Opin Infect Dis. 2013;26(5):454–460.
   PubMed Web of Science ®Google Scholar
• Shen NT, Maw A, Tmanova LL. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017;152(8):1889–1900.
   PubMed Web of Science ®Google Scholar
• Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.Br. J Cancer. 2007;97(8):1028–1034.
   Web of Science ®Google Scholar
• Benchimol E, Mack D. Probiotics in relapsing and chronic diarrhea. Journal of Pediatric Hematology/Oncology. 2004;26(8):515–517.
   PubMed Web of Science ®Google Scholar
• Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115(1):178–181.
   PubMed Web of Science ®Google Scholar
• Cohen SA, Woodfield MC, Boyle N, et al. Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations. Transpl Infect Dis. 2016;18(5):699–705.
   PubMed Web of Science ®Google Scholar
• Garey KW, Salazar M, Shah D, et al. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008;42(6):827–835.
   PubMed Web of Science ®Google Scholar
• Basu PP, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol. 2010;3(4):221–225.
   PubMedGoogle Scholar
• Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850–2855.
   PubMed Web of Science ®Google Scholar
• Anton PM, O’Brien M, Kokkotou E. Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother. 2004;48(10):3975–3979.
   PubMed Web of Science ®Google Scholar
• Nomura K, Matsumoto Y, Yoshida N, et al. Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin’s lymphoma. World J Gastroenterol. 2004;10(5):765–766.
   PubMed Web of Science ®Google Scholar
• Warren CA, van Opstal E, Ballard TE, et al. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection. model.Antimicrob Agents Chemother 2012;56(8):4103–4111.
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009;48(4):e41–6.
   PubMed Web of Science ®Google Scholar
• Popovic N, Korac M, Nesic Z, et al. Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection. J Infect Dev Ctries. 2015;9(10):1062–1067.
   PubMed Web of Science ®Google Scholar
• Wenisch C, Parschalk B, Hasenhündl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996 May;22(5):813–818.
   PubMed Web of Science ®Google Scholar
• Popovic N, Korac M, Nesic Z, et al. Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study. Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):745–754.
   PubMed Web of Science ®Google Scholar
• Thomas A, Khan F, Uddin N, et al. Tigecycline for severe Clostridium difficile infection. Int J Infect Dis. 2014;26:171–172.
   PubMed Web of Science ®Google Scholar
• Brinda B, Pasikhova Y, Quilitz R, et al. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections. Journal of Hospital Infection. 2017;95(4):426–432.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis. 2006;43(4):411–420.
   PubMed Web of Science ®Google Scholar
• McCoy RM, Klick A, Hill S, et al. Luminal toxin-binding agents for Clostridium difficile Infection. J Pharm Pract. 2016;29(4):361–367.
   PubMedGoogle Scholar
• Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345–354.
   PubMed Web of Science ®Google Scholar
• Shahani L, Koirala J, Intravenous immunoglobulin in treatment of Clostridium difficile colitis, Case Rep BMJ. 2012;2012. pii: bcr1020115052.
   Google Scholar
• Shah N, Shaaban H, Spira R, et al. Intravenous immunoglobulin in the treatment of severe clostridium difficile colitis. J Glob Infect Dis. 2014;6(2):82–85.
   PubMedGoogle Scholar
• Juang P, Skledar SJ, Zgheib NK. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control. 2007;35(2):1.
   PubMed Web of Science ®Google Scholar
• Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci. 2011;56(1):19–26.
   PubMed Web of Science ®Google Scholar
• Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315(2):142–149.
   PubMed Web of Science ®Google Scholar
• Van, Nood E VA, Nieuwdorp M. Duodenal infusion of donor faeces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415.
   PubMed Web of Science ®Google Scholar
• Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother. 2015;21(4):230–237.
   PubMed Web of Science ®Google Scholar
• Webb BJ, Brunner A, Ford CD, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2016;18(4):628–633.
   PubMed Web of Science ®Google Scholar
• Kali A, Charles MV, Cadazolid: SS. A new hope in the treatment of Clostridium difficile infection. Australas Med J. 2015;8(8):253–262.
   PubMed Web of Science ®Google Scholar
• Locher HH, Seiler P, Chen X, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for the treatment of Clostridium difficile infections: in vitro and in vivo antibacterial evaluation. Antimicrob Agents Chemother. 2014;58(2):892–900.
   PubMed Web of Science ®Google Scholar
• Locher HH, Caspers P, Bruyere T, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):901–908.
   PubMed Web of Science ®Google Scholar
• Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolidin patients with Clostridium difficile Infection. Antimicrob Agents Chemother. 2015;59(10):6266–6273.
   PubMed Web of Science ®Google Scholar
• Basseres E, Endres BT, Dotson KM, et al. Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017;33(1):1–7.
   PubMed Web of Science ®Google Scholar
• Daley P, Louie T, Lutz JE, et al. .Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, phase 3 trial. J Antimicrob Chemother. 2017;72(12):3462–3470.
   PubMed Web of Science ®Google Scholar
• Kraus CN, Lyerly MW, Carman RJ. .Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model. Antimicrob Agents Chemother. 2015;59(5):2525–2530.
   PubMed Web of Science ®Google Scholar
• Freeman J, Baines SD, Wilcox MH. Comparison of the efficacy of ramoplanin vs vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother. 2005;56(4):717–725.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. Difficile Infection: a Randomized Clinical Trial. JAMA.. 2015;313(17):1719–1727.
   PubMed Web of Science ®Google Scholar
• Valiquette L, Cossette B, Garant MP, et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 Strain. Clin Infect Dis. 2007;45(Suppl 2):S112–21.
   PubMed Web of Science ®Google Scholar
• Carignan A, Poulin S, Martin P, et al. Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections. Am J Gastroenterol. 2016;111(12):1834–1840.
   PubMed Web of Science ®Google Scholar
• Van Hise NW, Bryant AM, Hennessey EK, et al. Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents. Clin Infect Dis. 2016;63(5):651–653.
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305–317.
   PubMed Web of Science ®Google Scholar